Alnylam Pharmaceuticals, Inc.

LSE:0HD2 Stock Report

Market Cap: US$36.7b

Alnylam Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:0HD2 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Mar 25SellUS$308,141Jeffrey PoultonIndividual1,264US$248.36
03 Mar 25SellUS$180,402Kevin FitzgeraldIndividual740US$248.36
03 Mar 25SellUS$189,183Pushkal GargIndividual776US$248.36
03 Mar 25SellUS$114,820Tolga TangulerIndividual471US$247.35
03 Mar 25SellUS$945,165Yvonne GreenstreetIndividual3,877US$248.36
28 Feb 25SellUS$119,878Kevin FitzgeraldIndividual496US$244.11
14 Feb 25SellUS$169,204Kevin FitzgeraldIndividual663US$264.87
14 Feb 25SellUS$398,325Pushkal GargIndividual1,561US$264.87
14 Feb 25SellUS$246,750Jeffrey PoultonIndividual967US$264.87
14 Feb 25SellUS$309,527Yvonne GreenstreetIndividual1,213US$264.87
26 Nov 24SellUS$368,686Kevin FitzgeraldIndividual1,469US$252.27
26 Nov 24SellUS$422,144Jeffrey PoultonIndividual1,682US$252.27
26 Nov 24SellUS$368,686Tolga TangulerIndividual1,469US$252.27
26 Nov 24SellUS$422,144Pushkal GargIndividual1,682US$252.27
26 Nov 24SellUS$1,309,853Yvonne GreenstreetIndividual5,219US$252.27
25 Jun 24SellUS$370,747Jeffrey PoultonIndividual1,605US$235.19
25 Jun 24SellUS$485,773Pushkal GargIndividual2,103US$235.19
25 Jun 24SellUS$276,731Kevin FitzgeraldIndividual1,198US$235.19
25 Jun 24SellUS$370,747Tolga TangulerIndividual1,605US$235.19
25 Jun 24SellUS$1,917,475Yvonne GreenstreetIndividual8,301US$235.19

Insider Trading Volume

Insider Buying: 0HD2 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0HD2?
Owner TypeNumber of SharesOwnership Percentage
State or Government86,9150.0669%
Individual Insiders469,5040.362%
Public Companies4,444,4453.42%
Institutions124,837,07696.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 81.48% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.6%
Capital Research and Management Company
25,346,845US$7.2b-3.06%0.3%
10.2%
FMR LLC
13,185,416US$3.7b-8.16%0.2%
9.84%
The Vanguard Group, Inc.
12,733,399US$3.6b0.78%0.05%
7.64%
BlackRock, Inc.
9,885,228US$2.8b1.83%0.04%
5.95%
T. Rowe Price Group, Inc.
7,703,834US$2.2b16.9%0.17%
3.43%
Regeneron Pharmaceuticals, Inc.
4,444,445US$1.3b0%no data
3.24%
Wellington Management Group LLP
4,196,623US$1.2b-15.3%0.17%
3.12%
Baillie Gifford & Co.
4,040,259US$1.1b-17.3%0.45%
2.73%
Dodge & Cox
3,540,262US$1.0b-2.27%0.28%
2.64%
State Street Global Advisors, Inc.
3,422,877US$969.8m-1.31%0.03%
1.9%
Norges Bank Investment Management
2,456,082US$695.9m6.94%0.05%
1.7%
Geode Capital Management, LLC
2,206,800US$625.3m2.78%0.04%
1.54%
JP Morgan Asset Management
1,988,304US$563.4m9.01%0.05%
1.24%
American Century Investment Management Inc
1,604,024US$454.5m0.71%0.19%
1.14%
Orbis Investment Management Limited
1,472,802US$417.3m16.1%1.16%
0.79%
Winslow Capital Management, LLC
1,020,567US$289.2m40.5%0.95%
0.77%
UBS Asset Management AG
1,000,564US$283.5m16.1%0.02%
0.68%
Northern Trust Global Investments
878,860US$249.0m19.6%0.03%
0.64%
Legal & General Investment Management Limited
828,917US$234.9m4.7%0.04%
0.59%
Bellevue Asset Management AG
770,268US$218.2m-4.8%2.58%
0.57%
AQR Capital Management, LLC
736,011US$208.5m49.9%0.24%
0.4%
Charles Schwab Investment Management, Inc.
513,962US$145.6m5.46%0.02%
0.39%
TD Asset Management, Inc.
504,038US$142.8m3.23%0.09%
0.39%
Loomis Sayles & Company, L.P.
503,045US$142.5m-4.24%0.16%
0.38%
Amundi Asset Management SAS
497,504US$141.0m-16.1%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 01:34
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 60 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg